Skip to main content
. 2009 Dec 5;11(1):105–115. doi: 10.1007/s10198-009-0206-x

Table 5.

Costs and clinical outcomes (base-case analysis)

Palivizumab No prophylaxis Difference
Costs
 Direct medical costs (€) 7,490 1,169 6,321
 Direct medical costs + sequelae (€) 8,813 5,608 3,205
 Indirect costs (€) 1,034 4,634 −3,601
 Total costs (direct + indirect) (€) 9,846 10,242 −396
Outcomes
 Undiscounted
  Life-years lost 0.24 1.09 −0.85
  QALYs gained 77.22 76.19 1.03
 Discounted
  Life-years lost 0.10 0.43 −0.33
  QALYs gained 30.20 29.70 0.49

QALY Quality-adjusted life-year